Parathyroid carcinoma: New insights.

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-12-27 DOI:10.1016/j.beem.2024.101966

Abhishek Viswanath, Eftychia E Drakou, Fannie Lajeunesse-Trempe, Ashley B Grossman, Georgios K Dimitriadis

{"title":"Parathyroid carcinoma: New insights.","authors":"Abhishek Viswanath, Eftychia E Drakou, Fannie Lajeunesse-Trempe, Ashley B Grossman, Georgios K Dimitriadis","doi":"10.1016/j.beem.2024.101966","DOIUrl":null,"url":null,"abstract":"Parathyroid carcinoma (PC) is a rare malignancy, comprising 1 % of all cases of primary hyperparathyroidism (PHPT). This narrative review explores recent advances in PC management, with a focus on molecular insights, diagnostic advancements, surgical innovations, and emerging targeted therapies. Manuscripts published between 2023 and 2024 were obtained from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The review highlights advances in biochemical markers, such as circulating tumour cells (CTCs), and imaging modalities such as 18F-FDG PET/CT and 4D-CT, which are improving diagnostic accuracy. Surgical resection remains central to localised and metastatic disease management. For patients with widespread metastatic or unresectable disease, newer targeted approaches such as tyrosine kinase inhibitors (TKIs), temozolomide, and immune checkpoint inhibitors (ICIs) may offer clinical benefit to specific patient cohorts. This review identifies future research areas to improve outcomes and recommends that patients with advanced PC continue to be managed in centres of excellence.","PeriodicalId":93894,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":" ","pages":"101966"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best practice & research. Clinical endocrinology & metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.beem.2024.101966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Parathyroid carcinoma (PC) is a rare malignancy, comprising 1 % of all cases of primary hyperparathyroidism (PHPT). This narrative review explores recent advances in PC management, with a focus on molecular insights, diagnostic advancements, surgical innovations, and emerging targeted therapies. Manuscripts published between 2023 and 2024 were obtained from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The review highlights advances in biochemical markers, such as circulating tumour cells (CTCs), and imaging modalities such as ¹⁸F-FDG PET/CT and 4D-CT, which are improving diagnostic accuracy. Surgical resection remains central to localised and metastatic disease management. For patients with widespread metastatic or unresectable disease, newer targeted approaches such as tyrosine kinase inhibitors (TKIs), temozolomide, and immune checkpoint inhibitors (ICIs) may offer clinical benefit to specific patient cohorts. This review identifies future research areas to improve outcomes and recommends that patients with advanced PC continue to be managed in centres of excellence.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

甲状旁腺癌：新见解。

甲状旁腺癌（PC）是一种罕见的恶性肿瘤，占所有原发性甲状旁腺功能亢进（PHPT）病例的1% %。这篇叙述性综述探讨了PC管理的最新进展，重点是分子见解，诊断进展，手术创新和新兴的靶向治疗。2023年至2024年间发表的手稿来自PubMed、EMBASE和Cochrane中央对照试验登记册（Central）。这篇综述强调了生化标志物的进展，如循环肿瘤细胞（ctc），以及18F-FDG PET/CT和4D-CT等成像方式，这些都提高了诊断的准确性。手术切除仍然是局部和转移性疾病治疗的核心。对于广泛转移性或不可切除性疾病的患者，新的靶向治疗方法，如酪氨酸激酶抑制剂（TKIs）、替莫唑胺和免疫检查点抑制剂（ICIs）可能为特定患者群体提供临床益处。本综述确定了未来改善预后的研究领域，并建议晚期PC患者继续在卓越中心进行管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Best practice & research. Clinical endocrinology & metabolism

自引率

0.00%

发文量

期刊最新文献

Adolescent primary hyperparathyroidism. Localization in primary hyperparathyroidism. Parathyroid carcinoma: New insights. Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model. Recent discoveries of Sino-Caucasian differences in the genetics of phaeochromocytomas and paragangliomas.